Cutanix Study Details

[Guest guest]

I just received the following response from K. Pilcher,

Ph.D. Director of Research at Cutanix.

He says here that all the studies were double-blind placebo

controlled, although until (or indeed if) the studies are published

for review, we will have to take his word. Note that some of the

text is the same as that in the document most of us will have

already read.

I also asked him if any of the studies will be published in peer-

reviewed journals.

-- begin quote

We will be launching sales of this product at a National Skin Aging

Research Conference in Chicago next week and we are very excited at

the results we have obtained. To date, we have completed three

clinical studies with a nationally recognized dermatologist

investigating the effects of our product on UV-induced sunburn,

rosacea, and eczema. All studies performed were double blinded and

placebo controlled. For the eczema and rosacea studies 40 patients

(20 eczema, 20 rosacea) were enrolled and treated over a 4 week

course of Dramatic Relief lotion with 1% Quadrinone (or vehicle

alone-placebo group). During their first visit, patients were

evaluated by the dermatologist using 4 measurements of disease: 1)

erythema, 2) desquamation (peeling), 3) uneven skin tone,

and 4) dermatitis. The dermatologist also provided an " Overall

Severity " score, which ranged from 1-6 with 6 being the most severe

level of overall disease. Patients were photographed to record the

severity of the disease. After evaluation patients were sent home

with the Dramatic Relief lotion and told to apply it morning and

evening for two weeks. They then returned to the clinic for a two-

week evaluation and at that time received more product for an

additional 2 weeks. At four weeks, both the dermatologist and the

subjects evaluated the severity of their disease. Digital

photographs of the treated areas were also taken.

Of the 20 eczema patients that started the study, 17 completed the

four-week period. None of the subjects, including those who dropped

out, experienced any irritation reaction or other adverse effect

from the product. The severity of eczema decreased in 15/17 subjects

(88%). Average improvement among those responding was 67%. This

agrees with the anecdotal data Cutanix had acquired from volunteers

who used the product and is a statistically significant result.

Of the 20 rosacea patients that started the study, 18 completed the

four-week period. None of the subjects, including those who dropped

out, experienced any irritation reaction or other adverse effect

from the product. The severity of rosacea decreased in 13/18

subjects (72%). Average improvement among those responding was 68%.

This agrees with the anecdotal data Cutanix had acquired from

volunteers who used the product and is a statistically significant

result. cea is a much more difficult disease to treat than

eczema because of the severity of skin inflammation and

vasodilation. We were, therefore, particularly pleased by these

results.

Considering that a 2% formulation of Quadrinone has been shown

to be more effective in blocking UV-induced erythema than the 1%

formulation used in this clinical study, a higher strength version

of " Dramatic Relief " may provide even greater efficacy in treating

rosacea. Furthermore, Cutanix scientists have now identified even

more potent compounds related in structure to Quadrinone, and

these may prove more effective in treating severe dermatological

diseases.

-- end quote